- Titre
- Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Jun, 10.1007/s10067-022-06218-8, 2022)
- Créateurs - sans rôle
- Laura C. Coates - University of OxfordPhilip Mease - Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USAAndris Kronbergs - Eli Lilly & Co, Indianapolis, IN 46285 USACameron Helt - Eli Lilly & Co, Indianapolis, IN 46285 USADavid Sandoval - Eli Lilly & Co, Indianapolis, IN 46285 USASo Young Park - Eli Lilly & Co, Indianapolis, IN 46285 USABernard Combe - Univ Montpellier, Montpellier, FrancePeter Nash - The University of QueenslandAtul Deodhar - Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA
- Détails de publication
- Clinical rheumatology, Vol.41(10), p.3261-3261
- Éditeur
- Springer Nature
- Nombre de pages
- 1
- Note de subvention
- CS-2016-16-016; CL-2011-02-001 / National Institute for Health Research; National Institutes of Health Research (NIHR)
- Identifiants
- 99234101509311
- Unité académique
- IGMM - Institut de Génétique Moléculaire de Montpellier
- Langue
- Anglais
- Type de ressource
- Article de revue scientifique
Article de revue scientifique
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Jun, 10.1007/s10067-022-06218-8, 2022)
Clinical rheumatology, Vol.41(10), p.3261-3261
01/10/2022
PMID: 35821169
Indicateurs
1 Consultations de la notice